F017 Rheumatology for the Dermatologist: Evaluating the Rheumatology Patient in the Dermatology Clinic
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
The "Rheumatology for the Dermatologist" session at AAD 2025 will provide dermatologists with critical insights into evaluating and managing derm-rheum conditions in their practice. Through rapid-fire talks by leading experts, the session will cover systemic considerations and emerging therapies for dermatomyositis, systemic sclerosis, CLE, and morphea; screening and monitoring CLE-SLE progression; and diagnosing inflammatory arthritis, including PsA. Additional topics include serological markers in CTD and autoimmune skin disease management in cancer immunotherapy patients. Tailored for dermatologists, the session emphasizes collaborative care and staying updated on the intersection of dermatology and rheumatology.
LEARNING OBJECTIVES
Discuss updates in cutaneous lupus treatment including systemic lupus considerations for the dermatologist; describe dermatomyositis as defined by autoantibody profiles and outline the workup for the systemic sclerosis patient.
Appropriately order and interpret autoimmune serologic testing.
Develop a helpful review of systems to approach systemic rheumatologic disease.
SCHEDULE
6:00 PM
Dermatomyositis: systemic considerations for the dermatologist
Scott Elman, MD, FAAD
6:15 PM
Systemic sclerosis: systemic considerations for the dermatologist
Rebecca Gaffney, MD, FAAD
6:30 PM
Update in CLE Treatment and Collaborative Care Considerations for the CLE-SLE patient
Joseph Merola, MD, MSc, FAAD
6:45 PM
Risk factors for the progression of CLE to SLE: SLE screening and monitoring for the dermatologist
Benjamin F. Chong, MD, MSc, FAAD
7:00 PM
Inflammatory Arthritis for the Dermatologist: screening, diagnosis (and ddx) of PsA
Alice B. Gottlieb, MD, PhD, FAAD
7:15 PM
Serologies in CTD: What the dermatologist needs to know
Jeffrey Smith, PhD, MD, FAAD
7:30 PM
Current and emerging therapies for morphea
Heidi Tewich Jacobe, MD, FAAD
7:45 PM
Cutaneous autoimmune disease considerations in cancer immunotherapy
Meghan M. Heberton, MD, FAAD
SPEAKERS
Benjamin F. Chong, MD, MSc, FAAD
Scott Elman, MD, FAAD
Rebecca Gaffney, MD, FAAD
Alice B. Gottlieb, MD, PhD, FAAD
Meghan M. Heberton, MD, FAAD
Heidi Tewich Jacobe, MD, FAAD
Joseph Merola, MD, MSc, FAAD
Jeffrey Smith, PhD, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Benjamin F. Chong, MD, MSc, FAAD
Amgen – Other(Honoraria); AstraZeneca – Consultant (1099 relationship)(Fees); Biogen – Consultant(Honoraria), Investigator(Grants/Research Funding); Bristol-Myers Squibb – Consultant(Honoraria); Cesas Medical Limited – Speaker(Honoraria); EMD Serono – Consultant(Honoraria), Investigator(Grants/Research Funding); Horizon Pharma, Inc. – Consultant(Honoraria); Lupus Research Alliance – Consultant (1099 relationship)(Honoraria); MAPI Research Trust – Other(Patent royalties or other compensation for Intellectual Property Rights); Pfizer Inc. – Investigator(Grants/Research Funding);
Scott Elman, MD, FAAD
Biogen – Consultant(Fees); Bristol Myers Squibb – Investigator(Grants/Research Funding); EMD Serono – Consultant (1099 relationship)(Fees); Pfizer Inc. – Investigator(Grants/Research Funding);
Rebecca Gaffney, MD, FAAD
No financial relationships exist with ineligible companies.
Alice B. Gottlieb, MD, PhD, FAAD
amgen – Speaker/Faculty Education(Honoraria); BMS – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Boehringer Ingelheim – Advisory Board(Honoraria), Consultant(Honoraria); Eli Lilly – Consultant (1099 relationship)(Honoraria); janssen – Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Consultant(Honoraria); Novartis – Advisory Board(Honoraria), Consultant(Honoraria); Oruka Therapeutics – Advisory Board(Honoraria); Sanofi – Investigator(Grants/Research Funding); sanofi-aventis – Consultant (1099 relationship)(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria); ucb – Advisory Board(Honoraria); UCB – Investigator(Grants/Research Funding);
Meghan M. Heberton, MD, FAAD
Astellas Pharma US, Inc – Consultant (1099 relationship)(Fees); Blueprint Medicines – Advisory Board(Fees);
Heidi Tewich Jacobe, MD, FAAD
Bristol Myers Squibb – Other(No Compensation Received);
Joseph Merola, MD, MSc, FAAD
AbbVie – Consultant(Honoraria); Amgen – Advisory Board(Honoraria); AstraZeneca – Consultant (1099 relationship)(Fees); Biogen – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Consultant (1099 relationship)(Fees); Bristol-Myers Squibb – Consultant (1099 relationship)(Fees); Eli Lilly and Company – Consultant(Honoraria); Janssen Pharmaceuticals, Inc – Consultant(Honoraria); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Novartis – Consultant(Honoraria); Pfizer Inc. – Investigator(Fees); Sanofi/Regeneron – Consultant(Honoraria); UCB – Consultant(Honoraria);
Jeffrey Smith, PhD, MD, FAAD
Biogen – Investigator(Grants/Research Funding); Formation Bio – Consultant (1099 relationship)(Fees);